Boosting the cholinergic anti-inflammatory pathway with acetylcholinesterase inhibitors such as galantamine alleviates pathological attributes in SLE, including hypertension, inflammation, and renal injury, potentially by modulating B and T cells in the spleen and kidney. The gene discussed is ACHE; the disease is systemic lupus erythematosus.